發(fā)布時(shí)間：2018-04-29 01:40

  本文選題：卵巢漿液性上皮腫瘤 + PPARγ　； 參考：《蘇州大學(xué)》2014年碩士論文

【摘要】：目的：分別檢測(cè)卵巢漿液性囊腺瘤、交界性囊腺瘤和囊腺癌中PPARγ、M-CSF、CAl25和HE4的表達(dá)，初步探討PPARγ、M-CSF、CAl25和HE4在卵巢漿液性囊腺癌中的表達(dá)與其分化程度、病理分期及有無(wú)淋巴結(jié)轉(zhuǎn)移的關(guān)系。 方法：選取卵巢漿液性上皮腫瘤70例，其中囊腺瘤20例、交界性囊腺瘤10例、囊腺癌40例。以已知陽(yáng)性的乳腺癌切片作為陽(yáng)性對(duì)照，以PBS替代一抗作為陰性對(duì)照。采用免疫組化法對(duì)選取的70例卵巢漿液性上皮腫瘤進(jìn)行PPARγ、M-CSF、CAl25和HE4檢測(cè)，并分析其病理意義。 結(jié)果： 1. PPARγ在卵巢漿液性囊腺瘤組中的陽(yáng)性表達(dá)率(30.00%)低于交界性囊腺瘤(60.00%)和囊腺癌(72.50%)(P0.05)；M-CSF在囊腺瘤組中的陽(yáng)性表達(dá)率(10.00%)顯著低于交界性囊腺瘤(60.00%)和囊腺癌(70.00%)(P0.05)；CAl25在卵巢囊腺瘤組中的陽(yáng)性表達(dá)率(20.00%)低于交界性囊腺瘤(60.00%)和囊腺癌(65.00%)(P0.05)；HE4在囊腺瘤組中的陽(yáng)性表達(dá)率(0.00%)顯著低于交界性囊腺瘤(70.00%)和囊腺癌(80.00%)(P0.05)。 2. PPARγ、M-CSF、CAl25和HE4在卵巢漿液性囊腺癌中的表達(dá)皆與其分化程度呈負(fù)相關(guān)關(guān)系，與其臨床病理分期和有無(wú)淋巴轉(zhuǎn)移呈正相關(guān)關(guān)系。 3.與單項(xiàng)檢測(cè)相比，，PPARγ、M-CSF、CA125和HE4四者聯(lián)合檢測(cè)可以提高卵巢漿液性囊腺癌的診斷率。 結(jié)論： 1.PPARγ、M-CSF、CA125和HE4在卵巢漿液性上皮腫瘤中的表達(dá)與其病變程度、分化程度、臨床分期、有無(wú)淋巴轉(zhuǎn)移有一定的相關(guān)性。 2.PPARγ、M-CSF、CA125和HE4四者聯(lián)合檢測(cè)可以提高卵巢漿液性囊腺癌的診斷率，故有可能成為檢測(cè)卵巢漿液性囊腺癌的良好指標(biāo)。
[Abstract]:Objective: to detect the expression of PPAR 緯 -M-CSFFCAl25 and HE4 in serous cystadenoma, borderline cystadenoma and cystadenocarcinoma, and to explore the relationship between the expression of PPAR 緯 -M-CSFCal CAl25 and HE4 in ovarian serous cystadenocarcinoma and its differentiation, pathological stage and lymph node metastasis. Methods: 70 cases of ovarian serous epithelial tumors were selected, including 20 cases of cystadenoma, 10 cases of borderline cystadenoma and 40 cases of cystadenocarcinoma. Breast cancer sections with known positive results were used as positive controls and PBS as negative controls instead of first antibody. 70 cases of ovarian serous epithelial tumors were examined by immunohistochemical method for PPAR 緯 -M-CSFU CAl25 and HE4, and their pathological significance was analyzed. Results: 1. The positive expression rate of PPAR 緯 in ovarian serous cystadenoma group was significantly lower than that in borderline cystadenoma group (P 0.05 M CSF) and cystadenocarcinoma (72.50% P 0.05 M CSF) in ovarian cystadenoma group. The positive expression rate of PPAR 緯 in ovarian cystadenoma group was significantly lower than that in borderline cystadenoma group. The positive expression rate of cystadenocarcinoma and cystadenocarcinoma in cystadenoma group was significantly lower than that in borderline cystadenoma group (P 0.05) and cystadenocarcinoma group (P 0.05), and the positive expression rate of cystadenocarcinoma was significantly lower than that of borderline cystadenoma and cystadenocarcinoma (P 0.05). The positive expression rate of cystadenoma and cystadenocarcinoma was significantly lower than that of borderline cystadenoma and cystadenocarcinoma. 2. The expression of PPAR 緯 -M-CSFU CAl25 and HE4 in ovarian serous cystadenocarcinoma was negatively correlated with its differentiation, and positively correlated with its clinicopathologic stage and lymphatic metastasis. 3. Compared with single detection, combined detection of PPAR- 緯 -M-CSFCA125 and HE4 could improve the diagnosis rate of ovarian serous cystadenocarcinoma. Conclusion: The expression of 1.PPAR 緯 -M-CSFCF-CA125 and HE4 in ovarian serous epithelial tumors was correlated with the degree of lesion, differentiation, clinical stage and lymphatic metastasis. The combined detection of 2.PPAR 緯 M-CSF CA125 and HE4 can improve the diagnostic rate of ovarian serous cystadenocarcinoma, so it may be a good index for detecting ovarian serous cystadenocarcinoma.
【學(xué)位授予單位】：蘇州大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R737.31

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 范玉平;陶國(guó)華;;聯(lián)合檢測(cè)HE4和CA125對(duì)卵巢癌早期評(píng)估的價(jià)值[J];標(biāo)記免疫分析與臨床;2010年06期

2 魏濤,徐海英,陳艷萍;人巨噬細(xì)胞集落刺激因子(M—CSF)在卵巢癌診斷中的價(jià)值[J];放射免疫學(xué)雜志;2000年03期

3 鞠興東 ,徐博 ,袁文娟 ,張偉 ,魏濤;血清TSGF、CA-125、M-CSF在卵巢腫瘤診斷中的應(yīng)用評(píng)價(jià)[J];放射免疫學(xué)雜志;2003年01期

4 郭冰沁;俞嵐;武世伍;宋文慶;承澤農(nóng);;HE4、NF-κBp65和MMP-9在卵巢上皮性腫瘤中的表達(dá)及其臨床意義[J];中國(guó)組織化學(xué)與細(xì)胞化學(xué)雜志;2011年06期

5 徐新;潘繼存;江森;;細(xì)胞因子M-CSF與卵巢癌[J];國(guó)外醫(yī)學(xué)(免疫學(xué)分冊(cè));1998年03期

6 管桂峰;;OPN及HE4基因在上皮性卵巢癌中的表達(dá)及臨床意義[J];醫(yī)藥論壇雜志;2009年10期

7 王希芝,張友忠,林紅霞;卵巢癌的早期診斷研究進(jìn)展[J];現(xiàn)代婦產(chǎn)科進(jìn)展;2001年06期

8 何軍;韓輝;郭愛(ài)華;;血清CA125水平臨床意義的研究進(jìn)展[J];新疆醫(yī)科大學(xué)學(xué)報(bào);2007年05期

9 黃立,姚嘉斐;血清CA125檢測(cè)對(duì)卵巢上皮性癌預(yù)后的價(jià)值[J];中國(guó)婦幼保健;2005年13期

10 李巍,崔恒,馮捷,李藝;卵巢癌診斷的研究進(jìn)展[J];中華婦產(chǎn)科雜志;2005年07期

本文編號(hào)：1817849